Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation

K.L. Mcdonald, Tania Tabone, Anna Nowak, Wendy Erber

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

© 2015, Spandidos Publications. All rights reserved. The high level of methylguanine‑DNA methyltransferase (MGMT) in glioblastoma is responsible for resistance to alkylating agents, such as temozolomide (TMZ). In glioblastomas with a methylated MGMT promoter, MGMT deficiency is presumed, resulting in an enhanced effect of TMZ. The aim of the present study was to investigate whether genomic alterations work synergistically with MGMT methylation status and contribute to the response to treatment and overall prognosis in glioblastoma. The current study included a cohort of 35 glioblastoma patients, with MGMT promoter methylation present in 48% of tumors. MGMT methylation was associated with significantly longer median survival (29.0 months) compared with patients without MGMT methylated tumors (12.0 months), as well as longer median time to progression following TMZ treatment (13.2 months, compared with 5.6 months for patients with an unmethylated MGMT status). In addition, somatic variants in hot spot exonic regions of 50 key cancer genes were examined in these glioblastomas. Non‑synonymous mutations in methylated MGMT glioblastomas were four times higher compared with unmethylated MGMT glioblastomas. Furthermore, significantly increased frequencies of mutations in the TP53, CDKN2A, PTEN and PIK3CA genes were detected in MGMT methylated glioblastomas. The relative significance of these mutations, and their contribution to TMZ sensitivity, adjunct to MGMT methylation, require further investigation in a larger cohort.
Original languageEnglish
Pages (from-to)2063-2067
JournalOncology Letters
Volume9
Issue number5
DOIs
Publication statusPublished - 2015

Fingerprint

Methyltransferases
DNA Methylation
Glioblastoma
temozolomide
Mutation
Methylation
Neoplasm Genes
Alkylating Agents
Mutation Rate
Publications
Neoplasms

Cite this

@article{55e74bfc9b8844b3bec9ed3c2c76b007,
title = "Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation",
abstract = "{\circledC} 2015, Spandidos Publications. All rights reserved. The high level of methylguanine‑DNA methyltransferase (MGMT) in glioblastoma is responsible for resistance to alkylating agents, such as temozolomide (TMZ). In glioblastomas with a methylated MGMT promoter, MGMT deficiency is presumed, resulting in an enhanced effect of TMZ. The aim of the present study was to investigate whether genomic alterations work synergistically with MGMT methylation status and contribute to the response to treatment and overall prognosis in glioblastoma. The current study included a cohort of 35 glioblastoma patients, with MGMT promoter methylation present in 48{\%} of tumors. MGMT methylation was associated with significantly longer median survival (29.0 months) compared with patients without MGMT methylated tumors (12.0 months), as well as longer median time to progression following TMZ treatment (13.2 months, compared with 5.6 months for patients with an unmethylated MGMT status). In addition, somatic variants in hot spot exonic regions of 50 key cancer genes were examined in these glioblastomas. Non‑synonymous mutations in methylated MGMT glioblastomas were four times higher compared with unmethylated MGMT glioblastomas. Furthermore, significantly increased frequencies of mutations in the TP53, CDKN2A, PTEN and PIK3CA genes were detected in MGMT methylated glioblastomas. The relative significance of these mutations, and their contribution to TMZ sensitivity, adjunct to MGMT methylation, require further investigation in a larger cohort.",
author = "K.L. Mcdonald and Tania Tabone and Anna Nowak and Wendy Erber",
year = "2015",
doi = "10.3892/ol.2015.2980",
language = "English",
volume = "9",
pages = "2063--2067",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "5",

}

Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation. / Mcdonald, K.L.; Tabone, Tania; Nowak, Anna; Erber, Wendy.

In: Oncology Letters, Vol. 9, No. 5, 2015, p. 2063-2067.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation

AU - Mcdonald, K.L.

AU - Tabone, Tania

AU - Nowak, Anna

AU - Erber, Wendy

PY - 2015

Y1 - 2015

N2 - © 2015, Spandidos Publications. All rights reserved. The high level of methylguanine‑DNA methyltransferase (MGMT) in glioblastoma is responsible for resistance to alkylating agents, such as temozolomide (TMZ). In glioblastomas with a methylated MGMT promoter, MGMT deficiency is presumed, resulting in an enhanced effect of TMZ. The aim of the present study was to investigate whether genomic alterations work synergistically with MGMT methylation status and contribute to the response to treatment and overall prognosis in glioblastoma. The current study included a cohort of 35 glioblastoma patients, with MGMT promoter methylation present in 48% of tumors. MGMT methylation was associated with significantly longer median survival (29.0 months) compared with patients without MGMT methylated tumors (12.0 months), as well as longer median time to progression following TMZ treatment (13.2 months, compared with 5.6 months for patients with an unmethylated MGMT status). In addition, somatic variants in hot spot exonic regions of 50 key cancer genes were examined in these glioblastomas. Non‑synonymous mutations in methylated MGMT glioblastomas were four times higher compared with unmethylated MGMT glioblastomas. Furthermore, significantly increased frequencies of mutations in the TP53, CDKN2A, PTEN and PIK3CA genes were detected in MGMT methylated glioblastomas. The relative significance of these mutations, and their contribution to TMZ sensitivity, adjunct to MGMT methylation, require further investigation in a larger cohort.

AB - © 2015, Spandidos Publications. All rights reserved. The high level of methylguanine‑DNA methyltransferase (MGMT) in glioblastoma is responsible for resistance to alkylating agents, such as temozolomide (TMZ). In glioblastomas with a methylated MGMT promoter, MGMT deficiency is presumed, resulting in an enhanced effect of TMZ. The aim of the present study was to investigate whether genomic alterations work synergistically with MGMT methylation status and contribute to the response to treatment and overall prognosis in glioblastoma. The current study included a cohort of 35 glioblastoma patients, with MGMT promoter methylation present in 48% of tumors. MGMT methylation was associated with significantly longer median survival (29.0 months) compared with patients without MGMT methylated tumors (12.0 months), as well as longer median time to progression following TMZ treatment (13.2 months, compared with 5.6 months for patients with an unmethylated MGMT status). In addition, somatic variants in hot spot exonic regions of 50 key cancer genes were examined in these glioblastomas. Non‑synonymous mutations in methylated MGMT glioblastomas were four times higher compared with unmethylated MGMT glioblastomas. Furthermore, significantly increased frequencies of mutations in the TP53, CDKN2A, PTEN and PIK3CA genes were detected in MGMT methylated glioblastomas. The relative significance of these mutations, and their contribution to TMZ sensitivity, adjunct to MGMT methylation, require further investigation in a larger cohort.

U2 - 10.3892/ol.2015.2980

DO - 10.3892/ol.2015.2980

M3 - Article

VL - 9

SP - 2063

EP - 2067

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 5

ER -